Molecular forms of PSA;Les formes moléculaires du PSA

Progres en Urologie

Volumn 17, Issue 2, 2007, Pages 165-171

  Benchikh El Fegoun, Amine ^a   Villers, Arnauld ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Complexed PSA; Free PSA; proPSA; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN PRECURSOR; TISSUE KALLIKREIN;

BLOOD; CANCER STAGING; CLASSIFICATION; HUMAN; MALE; PATHOLOGY; PROSTATE TUMOR; REVIEW; SENSITIVITY AND SPECIFICITY;

HUMANS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY; TISSUE KALLIKREINS;

EID: 34250636380     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1166-7087(07)92255-1     Document Type: Article

References (38)

1. STENMAN U.H., LEINONEN J., ALFTHAN H., RANNIKKO S., TUHKANEN K., ALFTHAN O. : A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer : assay of the complex improves clinical sensitivity for cancer. Cancer Res., 1991 ; 51 : 222-226.
2. CATALONA W.J., PARTIN A.W., SLAWIN K.M., BRAWER M.K., FLANIGAN R.C., PATEL A., ET AL. : Use of the percentage of free prostatespecific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. Jama, 1998 ; 279 : 1542-1547.
3. DJAVAN B., REMZI M., ZLOTTA A.R., RAVERY V., HAMMERER P., REISSIGL A., ET AL. : Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen : results of the prospective multicenter European trial. Urology, 2002 ; 60 : 4-9.
4. PARTIN A.W., BRAWER M.K., BARTSCH G., HORNINGER W., TANEJA S.S., LEPOR H., ET AL. : Complexed prostate specific antigen improves specificity for prostate cancer detection : results of a prospective multicenter clinical trial. J. Urol., 2003 ; 170 : 1787-1791.
5. RODDAM A.W., DUFFY M.J., HAMDY F.C., WARD A.M., PATNICK J., PRICE C.P., ET AL. : Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml : systematic review and meta-analysis. Eur. Urol., 2005 ; 48 : 386-399.
6. ROEHL K.A., ANTENOR JA., CATALONA W.J. : Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. J. Urol., 2002 ; 168 : 922-5.
7. RAAIJMAKERS R., BLIJENBERG B.G., FINLAY J.A., RITTENHOUSE H.G., WILDHAGEN M.F., ROOBOL M.J., ET AL. : Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml : value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J. Urol., 2004 ; 171 : 2245-2249.
8. VAN CANGH P.J., DE NAYER P., DE VISCHER L., SAUVAGE P., TOMBAL B., LORGE F., ET AL. : Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA. Urology, 1996 ; 48 : 67-70.
9. CANTO E.I., SINGH H., SHARIAT S.F., KADMON D., MILES B.J., WHEELER T.M., ET AL. : Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J. Urol., 2004 ; 172 : 900-904.
10. DAVER A. DI. : Quel avenir pour les marqueurs tumoraux sériques ? Mise à jour des systèmes et techniques de dosage. Spectra Biologie, 1999 : 28-38.
11. STEPHAN C., LEIN M., JUNG K., SCHNORR D., LOENING S.A. : The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer, 1997 ; 79 : 104-109.
12. SOKOLL L.J., BRUZEK D.J., DUA R., DUNN W., MOHR P., WALLERSON G., ET AL. : Short-term stability of the molecular forms of prostatespecific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. Urology, 2002 ; 60 : 24-30.
13. OBERPENNING F., WEINING C., BRANDT B., DE ANGELIS G., HEINECKE A., HAMM M., et al. : Combining free and total prostate specific antigen assays from different manufacturers : the pitfalls. Eur. Urol., 2002 ; 42 : 577-582.
14. AUS G., BECKER C., FRANZEN S., LILJA H., LODDING P., HUGOSSON J. : Cumulative prostate cancer risk assessment with the aid of the freeto-total prostate specific antigen ratio. Eur. Urol., 2004 ; 45 : 160-165.
15. CATALONA WJ., SOUTHWICK P.C., SLAWIN K.M., PARTIN A.W., BRAWER M.K., FLANIGAN R.C., ET AL. : Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000 ; 56 : 255-260.
16. MELCHIOR S.W., NOTEBOOM J., GILLITZER R., LANGE P.H., BLUMENSTEIN BA., VESSELLA R.L. : The percentage of free prostate-specific antigen does not predict extracapsular disease in patients with clinically localized prostate cancer before radical prostatectomy. BJU Int., 2001 ; 88 : 221-225.
17. TOMBAL B., QUERTON M., DE NAYER P., SAUVAGE P., COSYNS J.P., FEYAERTS A., ET AL. : Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy. Urology, 2002 ; 59 : 256-260.
18. NAYA Y., FRITSCHE H.A., CHELI C.D., STAMEY T.A., BARTSCH G., BRAWER M.K., ETAL. : Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. Urology, 2003 ; 62 : 1058-1062.
19. TORNBLOM M., NORMING U., BECKER C., LILJA H., GUSTAFSSON O. : Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level. BJU Int., 2001 ; 87 : 638-642.
20. GRETZENBERG RH. : Advances in biomarkers for prostate diseases. In : G. Murphy SK, Partin A., Denis L., editor. Prostate Cancer 4th Edition International consultation on prostate diseases. 4th ed. Paris : Resnick MI. et al.; 2005.
21. VILLERS A., CHAUTARD D. : PSA libre: l'utilisation en routine est prématurée pour le dépistage du cancer de la prostate. Prog Urol., 2000 ; 10 : 618-621.
22. RAVERY V. CD, VILLERS A., LEFRANC D., BOCCON-GIBOD L. : Complexed PSA For Early Detection Of Prostate Cancer : A Multi Institutional Study J. Urol. Suppl Abstract, 2004.
23. PARSONS J.K., PARTIN A.W. : Applying complexed prostate-specific antigen to clinical practice. Urology, 2004 ; 63 : 815-818.
24. SOZEN S., ESKICORAPCI S., KUPELI B., IRKILATA L., ALTINEL M., OZER G., ET AL. : Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml : results of a prospective multicenter study. Eur. Urol., 2005 ; 47 : 302-307.
25. LEIN M., KWIATKOWSKI M., SEMJONOWA., LUBOLDT H.J., HAMMERER P., STEPHAN C., ET AL. : A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J. Urol., 2003 ; 170 : 1175-1179.
26. HORNINGER W., CHELI C.D., BABAIAN R.J., FRITSCHE H.A., LEPOR H., TANEJA S.S., ET AL. : Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology, 2002 ; 60 : 31-35.
27. ALLARD W.J., CHELI CD., MORRIS D.L., GOLDBLATT J., PIERRE Y., KISH L., ET AL. : Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immuno 1 complexed PSA assay. Int. J. Biol. Markers, 1999 ; 14 : 73-83.
28. BALK S.P., KO Y.J., BUBLEY G.J. : Biology of prostate-specific antigen. J. Clin. Oncol., 2003 ; 21 : 383-391.
29. CATALONA W.J., BARTSCH G., RITTENHOUSE H.G., EVANS C.L., LINTON H.J., AMIRKHAN A., ET AL. : Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J. Urol., 2003 ; 170 : 2181-2185.
30. LEIN M., SEMJONOW A., GRAEFEN M., KWIATKOWSKI M., ABRAMJUK C., STEPHAN C., ET AL. : A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J. Urol., 2005 ; 174 : 2150-2153.
31. NURMIKKO P., PETTERSSON K., PIIRONEN T., HUGOSSON J., LILJA H. : Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin. Chem., 2001 ; 47 : 1415-1423.
32. STEUBER T., NIEMELA P., HAESE A., PETTERSSON K., ERBERSDOBLERA., FELIX CHUN K.H., ET AL. : Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate, 2005 ; 63 : 13-18.
33. PARTIN A.W., CATALONA WJ., FINLAY J.A., DARTE C., TINDALL DJ., YOUNG C.Y., ET AL. : Use of human glandular kallikrein 2 for the detection of prostate cancer : preliminary analysis. Urology, 1999 ; 54 : 839-845.
34. BECKER C., PIIRONEN T., PETTERSSON K., HUGOSSON J., LILJA H.: Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology, 2000 ; 55 : 694-699.
35. MIKOLAJCZYK S.D., GRAUER L.S., MILLAR L.S., HILL T.M., KUMAR A., RITTENHOUSE H.G., ET AL. : A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology, 1997 ; 50 : 710-714.
36. LINTON H.J., MARKS L.S., MILLAR L.S., KNOTT CL., RITTENHOUSE H.G., MIKOLAJCZYK S.D. : Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin. Chem., 2003 ; 49 : 253-259.
37. CANTO E.I., SINGH H., SHARIAT S.F., LAMB D.J., MIKOLAJCZYK S.D., LINTON H.J., ET AL. : Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology. 2004 ; 63 : 905-910.
38. OESTERLING J.E., JACOBSEN S.J., KLEE G.G., PETTERSSON K., PIIRONEN T., ABRAHAMSSON P.A., ET AL. : Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J. Urol., 1995 ; 154 : 1090-1095.